Claris Financial LLC Buys Shares of 6,229 Merck & Co., Inc. $MRK

Claris Financial LLC bought a new stake in Merck & Co., Inc. (NYSE:MRK) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 6,229 shares of the company’s stock, valued at approximately $656,000.

Several other hedge funds and other institutional investors also recently modified their holdings of MRK. Chesapeake Wealth Management lifted its position in Merck & Co., Inc. by 0.6% in the 4th quarter. Chesapeake Wealth Management now owns 14,740 shares of the company’s stock valued at $1,552,000 after purchasing an additional 87 shares during the last quarter. South Plains Financial Inc. boosted its stake in Merck & Co., Inc. by 0.6% during the 4th quarter. South Plains Financial Inc. now owns 15,535 shares of the company’s stock valued at $1,635,000 after purchasing an additional 89 shares during the period. Syverson Strege & Co grew its position in Merck & Co., Inc. by 2.2% in the 4th quarter. Syverson Strege & Co now owns 4,142 shares of the company’s stock worth $436,000 after purchasing an additional 90 shares during the last quarter. Westside Investment Management Inc. grew its position in Merck & Co., Inc. by 3.1% in the 4th quarter. Westside Investment Management Inc. now owns 3,142 shares of the company’s stock worth $331,000 after purchasing an additional 93 shares during the last quarter. Finally, Valued Wealth Advisors LLC grew its position in Merck & Co., Inc. by 26.9% in the 4th quarter. Valued Wealth Advisors LLC now owns 444 shares of the company’s stock worth $47,000 after purchasing an additional 94 shares during the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on MRK shares. Barclays assumed coverage on Merck & Co., Inc. in a report on Friday, February 20th. They set an “overweight” rating and a $140.00 price target on the stock. JPMorgan Chase & Co. increased their price objective on Merck & Co., Inc. from $125.00 to $135.00 and gave the stock an “overweight” rating in a report on Monday, April 6th. UBS Group raised their target price on Merck & Co., Inc. from $130.00 to $145.00 and gave the company a “buy” rating in a research report on Monday, April 13th. Citigroup started coverage on Merck & Co., Inc. in a research note on Wednesday, May 6th. They set a “neutral” rating and a $125.00 target price on the stock. Finally, Wells Fargo & Company reduced their price target on Merck & Co., Inc. from $150.00 to $145.00 and set an “overweight” rating for the company in a research report on Friday, May 1st. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and seven have assigned a Hold rating to the stock. According to data from MarketBeat.com, Merck & Co., Inc. has a consensus rating of “Moderate Buy” and an average target price of $128.18.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: The U.S. FDA approved an additional indication for CAPVAXIVE, Merck’s pneumococcal vaccine, expanding its use to children and adolescents ages 2 through 17 at increased risk for pneumococcal disease. The expanded label could support longer-term sales growth and reinforces Merck’s vaccine franchise. Article Title
• Neutral Sentiment: Merck also announced broader corporate activity around AI drug discovery with Protillion Biosciences and a global HPV awareness campaign, which may help pipeline development and brand visibility over time but are not immediate revenue drivers. Article Title
• Neutral Sentiment: A separate survey from Merck Animal Health highlighted unmet needs in treating canine allergic skin disease, suggesting future product opportunity, but it is a relatively small and less immediate catalyst for the stock. Article Title
• Negative Sentiment: Despite the FDA win, MRK has still been trading lower recently, reflecting broader weakness in the shares and suggesting investors may be waiting for more evidence that new and existing products can offset slower growth in other parts of the portfolio. Article Title

Merck & Co., Inc. Stock Down 1.2%

MRK stock opened at $114.04 on Friday. Merck & Co., Inc. has a 52 week low of $76.66 and a 52 week high of $125.14. The company has a market capitalization of $281.65 billion, a price-to-earnings ratio of 32.12, a price-to-earnings-growth ratio of 2.60 and a beta of 0.21. The firm’s 50-day moving average is $116.12 and its two-hundred day moving average is $113.60. The company has a current ratio of 1.30, a quick ratio of 1.06 and a debt-to-equity ratio of 1.02.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.19. The company had revenue of $16.29 billion during the quarter, compared to analyst estimates of $15.85 billion. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The business’s revenue for the quarter was up 4.9% compared to the same quarter last year. During the same period in the prior year, the business posted $2.22 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, analysts forecast that Merck & Co., Inc. will post 5.17 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 8th. Shareholders of record on Monday, June 15th will be given a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a yield of 3.0%. The ex-dividend date is Monday, June 15th. Merck & Co., Inc.’s dividend payout ratio is 95.77%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.